Recipient should be considered a “luminary” in the field and have significantly contributed to the advancement of cancer immunotherapy research. Society membership is not a requirement to receive this award. 

Along with name of nominee, nominator must provide one nomination letter (2 page limit) and the nominee’s CV. See more information including previous winners of the Smalley Award here.

• Actively serving FAIO Committee members or Board members will not be eligible for nomination. After members rotate off the Committee or Board, they may be considered for nomination. SITC Staff will notify nominators if this is the case.
• Fellows should commit to attending the induction ceremony event held in conjunction with the Annual Meeting to be eligible to receive the award. The SITC 38^th Annual Meeting & Pre-Conference Programs (SITC 2023) will take place on Nov. 1–5, 2023, at San Diego Convention Center in San Diego.
• Work setting is not a limiting factor for the FAIO, all those who are a part of academia, industry, other, etc. are eligible.
• SITC membership is not a requirement for nominees.
• The FAIO Committee may opt to honor one posthumous awardee with each class.
• Inducted Fellows of the Academy of IO will be called upon to help in the selection of subsequent classes of inductees.
  

Along with name of nominee, nominator must provide one nomination letter (2 page limit) and the nominee’s CV. See more information including previous Fellows of the Academy of Immuno-Oncology here.

• Nominee has demonstrated a lifelong commitment to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy 
• Nominee’s service and/or leadership has made a significant impact on SITC’s development and mission
• Nominee’s contributions can include program development, service, leadership, mentorship and/or advocacy within SITC

Nominator should supply one letter (2 page limit) and the nominee's CV. The nomination letter should address how the nominee impacted SITC's mission using the criteria listed. 

Candidates for the Tara Withington Public Service Award should have demonstrated outstanding leadership and accomplishment in meeting any of the following selection criteria:

• Increased the public's understanding and fostered awareness of cancer immunotherapy through innovation and communication to the public, and encouraged others to follow suit
• Advocated for and championed progress in the field of cancer immunotherapy 
• Promoted the engagement of the public in outreach, advocacy and promotion of cancer immunotherapy 
• Contributed to the development of cancer immunotherapy policies and their support 
• Influenced and encouraged the next generation of cancer immunotherapy scientists and clinicians 
• Encouraged and facilitated collaboration between entities in the cancer immunotherapy field

Along with name of nominee(s), nominator must provide a brief description (2 page limit) that includes a description of the nominee's public service to the field of cancer immunotherapy. Please specifically comment on how the nominee(s) met one or more of the criteria listed. 

Recipient has significantly contributed to the advancement of the journal and its aims through their distinguished record of service, leadership, and/or collaboration. Society membership is not a requirement to receive this award.

Along with name of nominee, nominator must provide a brief description (2 page limit) of their service to the Journal for ImmunoTherapy of Cancer (JITC).